Browse Studies — Arctuva

Phase 3

COVE-3: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epi…

Common WartsCommon Warts (Verruca Vulgaris)Human Papilloma Virus (HPV)+1 more

Estimated

~$10 – $8,750

Verrica Pharmaceuticals Inc.NCT07637734

Phase 3

COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epi…

Common WartsCommon Warts (Verruca Vulgaris)Human Papilloma Virus (HPV)+1 more

Estimated

~$10 – $8,750

Verrica Pharmaceuticals Inc.NCT07246590

Phase 3

COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The…

Common Warts (Verruca Vulgaris)Common WartsHuman Papilloma Virus (HPV)+1 more

Estimated

~$10 – $8,750

Verrica Pharmaceuticals Inc.NCT07457918